Phillip Lynch appointed Director of Race
Released
Released
Announcement PDF
1 June 2020
ASX Announcement
Phillip Lynch appointed Director of Race
• Mr Phillip Lynch, former Vice President Commercial Growth & Innovation for Johnson & Johnson
Asia Pacific, joins Race as Non-Executive Director
• Appointment brings further, deep commercial experience to Race’s Board
• Mr Lynch to strengthen Race’s outreach in the Asia Pacific region
1 June 2020 – Race Oncology Limited (ASX: RAC) is pleased to announce that Mr Phillip R Lynch has
been appointed to the Board as an independent Non-Executive Director.
Mr Lynch joins Race following a career spanning more than 30 years in the Asia Pacific region with
Johnson & Johnson. He is an experienced executive and board director, with a diverse background
across corporate development, strategy, financial performance, marketing and governance.
In his former role as Vice President of Commercial Growth & Innovation at Johnson & Johnson Asia
Pacific (J&J AP, 2016 - 2019), Mr Lynch partnered with the Mergers & Acquisitions team to drive the
integration and growth of acquired businesses. He retired from J&J AP in December 2019 following
the >$2b acquisition and integration of a significant Japanese business.
Mr Lynch was previously the Managing Director and CEO of J&J Pacific (AU/NZ) where he led J&J Pacific
to significant growth in revenue and profitability (2009 to 2015). He had further leadership roles across
the Asia Pacific region, including Managing Director of various J&J divisions in Thailand, Vietnam and
Singapore.
Phillip was also a member of the J&J Corporate Australian Board working across the Consumer,
Medical and Pharmaceutical businesses. He was Non-Executive Director of a US based e-commerce
Logistics start up that was successfully scaled and sold in 2013.
Mr Lynch is a graduate of Monash University with a Bachelor of Business in Marketing. He has
completed post-graduate studies at University of Virginia’s Darden Business School (USA) and is a
Graduate of the Australian Institute of Company Directors.
“We welcome Phil to the Race team and we all look forward to working with him as we move Race
forward. His experience in M&A and corporate strategy in the Asia Pacific region will be a huge asset
to Race as we execute on our 5-Path strategy.” said Race Oncology Executive Chairman, Dr John Cullity.
Mr Phillip Lynch commented, “Race brings together a highly capable team and a developed strategy
for its differentiated drug which possesses clear activity in leukemia and the promise of additional
treatment applications. I look forward to joining the Board and working with the team to see
Bisantrene commercialised globally benefitting cancer patients and the business’ broader
stakeholders.”
-
ENDS
-
Race Oncology Limited ABN 61 149 318 749
Registered office: L40, 140 William St, Melbourne VIC 3004
www.raceoncology.com
About Race Oncology (ASX: RAC)
Race Oncology (RAC) is a drug development biotech with a Phase II/III cancer drug called Bisantrene.
RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML) as well as breast
and ovarian cancer. RAC is pursuing an exciting ‘5-Path’ clinical development strategy that involves
parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020.
Release authorised by:
Media contact:
John Cullity, Executive Chairman
Henry Jordan, Six Degrees Investor Relations
john@biosynergypartners.com
+61 411 272 366
henry.jordan@sdir.com.au
Dr Daniel Tillett, Chief Operating Officer & Director
daniel.tillett@raceoncology.com
Share your feedback
Discover